Misti Linaberry

618 total citations · 2 hit papers
6 papers, 407 citations indexed

About

Misti Linaberry is a scholar working on Immunology, Pathology and Forensic Medicine and Dermatology. According to data from OpenAlex, Misti Linaberry has authored 6 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 3 papers in Pathology and Forensic Medicine and 2 papers in Dermatology. Recurrent topics in Misti Linaberry's work include Psoriasis: Treatment and Pathogenesis (5 papers), Autoimmune Bullous Skin Diseases (3 papers) and Inflammatory mediators and NSAID effects (1 paper). Misti Linaberry is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (5 papers), Autoimmune Bullous Skin Diseases (3 papers) and Inflammatory mediators and NSAID effects (1 paper). Misti Linaberry collaborates with scholars based in United States, Canada and Germany. Misti Linaberry's co-authors include John Throup, Bruce Strober, Diamant Thaçi, Sudeep Kundu, Subhashis Banerjee, Kim Papp, Melinda Gooderham, Shinichi Imafuku, Richard B. Warren and Andrew Blauvelt and has published in prestigious journals such as Journal of the American Academy of Dermatology, JAMA Dermatology and Clinical and Experimental Dermatology.

In The Last Decade

Misti Linaberry

5 papers receiving 401 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

2022 173 citations Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology profile →

Peers

Countries citing papers authored by Misti Linaberry

Since Specialization

Citations

This map shows the geographic impact of Misti Linaberry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Misti Linaberry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Misti Linaberry more than expected).

Fields of papers citing papers by Misti Linaberry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Misti Linaberry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Misti Linaberry. The network helps show where Misti Linaberry may publish in the future.

Co-authorship network of co-authors of Misti Linaberry

This figure shows the co-authorship network connecting the top 25 collaborators of Misti Linaberry. A scholar is included among the top collaborators of Misti Linaberry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Misti Linaberry. Misti Linaberry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

#	Work	Indexed citations
1	Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis 2025 ·Clinical and Experimental Dermatology ·Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Tiago Torres, Zoran Popmihajlov, Ying-Ming Jou, Misti Linaberry, (unknown), C.E.M. Griffiths	0
2	Cendakimab in Patients With Moderate to Severe Atopic Dermatitis 2024 ·JAMA Dermatology ·Andrew Blauvelt, Emma Guttman‐Yassky, Charles Lynde, Saakshi Khattri, Joel Schlessinger, (unknown), Yayoi Tada, Akimichi Morita, Marni Wiseman, Bartłomiej Kwiek, (unknown), Peijin Zhang, Misti Linaberry, Jie Li, (unknown), Giovanni Franchin, Edgar D. Charles, (unknown), (unknown)	11
3	Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary 2023 ·Immunotherapy ·Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, C. Paul, Jerry Bagel, (unknown), John Throup, Sudeep Kundu, (unknown), Misti Linaberry, Subhashis Banerjee, Kim Papp	2
4	Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary 2023 ·Immunotherapy ·April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, (unknown), John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt	2
5	Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial breakdown → 2022 ·Journal of the American Academy of Dermatology ·April W. Armstrong, Melinda Gooderham, Richard B. Warren, Kim Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C. Szepietowski, Shinichi Imafuku, (unknown), John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt	219
6	Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial breakdown → 2022 ·Journal of the American Academy of Dermatology ·Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B. Gordon, Peter Foley, Phoebe Rich, C. Paul, Jerry Bagel, (unknown), John Throup, Sudeep Kundu, (unknown), Misti Linaberry, Subhashis Banerjee, Kim Papp	173

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact